Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

2.050 -0.030 (-1.44%)
Streaming Delayed Price Updated: 3:55 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,913
Open 2.080
Bid (Size) 2.000 (59)
Ask (Size) 2.050 (1)
Prev. Close 2.080
Today's Range 2.030 - 2.137
52wk Range 1.710 - 7.260
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Stress-Related Mood Disorders And Alzheimer's: Can This Patented Ketamine Drug Help?
Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and... 
Via Benzinga

Performance

YTD
-33.22%
-33.22%
1 Month
-4.65%
-4.65%
3 Month
-6.82%
-6.82%
6 Month
-44.14%
-44.14%
1 Year
-59.80%
-59.80%

More News

Read More
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation at Upcoming Psychedelic Drug Development Conference
Via Investor Brand Network
Silo Pharma to Present at Psychedelic Drug Development Conference
From Silo Pharma, Inc.
Via GlobeNewswire
Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Development of Treatment for Anxiety-Related Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
Via FinancialNewsMedia
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Via Benzinga
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia
Via Investor Brand Network
Silo Pharma To Patent Novel Ketamine-Based Treatment For Chronic Condition
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.